ID   WM902B-BR
AC   CVCL_VK52
SY   WM902B-R; WM902-BR
DR   cancercelllines; CVCL_VK52
DR   Cosmic; 2838887
DR   Wikidata; Q98134964
RX   PubMed=21156289;
RX   PubMed=27500726;
CC   Part of: Wistar Institute melanoma cell line collection.
CC   Selected for resistance to: ChEBI; CHEBI:131882; SB-590885.
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=21156289).
CC   Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Leu (c.71G>T); ClinVar=VCV000376377; Zygosity=Unspecified (PubMed=21156289).
CC   Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Lys1083Ter (c.3247A>T); Zygosity=Unspecified (PubMed=27500726).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_6807 ! WM902B
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 05-10-23; Version: 8
//
RX   PubMed=21156289; DOI=10.1016/j.ccr.2010.11.023;
RA   Villanueva J., Vultur A., Lee J.T., Somasundaram R.,
RA   Fukunaga-Kalabis M., Cipolla A.K., Wubbenhorst B., Xu X.-W.,
RA   Gimotty P.A., Kee D., Santiago-Walker A.E., Letrero R., D'Andrea K.,
RA   Pushparajan A., Hayden J.E., Dahlman K.B., Laquerre S.G., McArthur G.A.,
RA   Sosman J.A., Nathanson K.L., Herlyn M.;
RT   "Acquired resistance to BRAF inhibitors mediated by a RAF kinase
RT   switch in melanoma can be overcome by cotargeting MEK and
RT   IGF-1R/PI3K.";
RL   Cancer Cell 18:683-695(2010).
//
RX   PubMed=27500726; DOI=10.1038/nm.4155;
RA   Shen C.-H., Kim S.H., Trousil S., Frederick D.T., Piris A., Yuan P.,
RA   Cai L., Gu L., Li M., Lee J.H., Mitra D., Fisher D.E., Sullivan R.J.,
RA   Flaherty K.T., Zheng B.;
RT   "Loss of cohesin complex components STAG2 or STAG3 confers resistance
RT   to BRAF inhibition in melanoma.";
RL   Nat. Med. 22:1056-1061(2016).
//